Drugs / ARO-ALK7
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | — | obesity disorder | 2024-12-03 | “Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7,” arrowheadpharma.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06937203 | May 2025 → Feb 2027 expected | obesity disorder, type 2 diabetes mellitus | Arrowhead Pharmaceuticals | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-01-06 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition arrowheadpharma.com ↗
ARO-ALK7 is the first RNAi-therapeutic to show knockdown in humans of an adipocyte expressed gene and achieved a mean reduction of -88% in ALK7 mRNA with a maximum reduction of -94% |
| 2025-03-06 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. |
| 2025-02-25 | Arrowhead Pharmaceuticals | Results Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity arrowheadpharma.com ↗
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. |
| 2024-12-23 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity arrowheadpharma.com ↗
Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. |
| 2024-12-03 | Arrowhead Pharmaceuticals | Regulatory Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity arrowheadpharma.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARO-ALK7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06937203 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) injection” NCT06937203 ↗ |